Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy

This study is currently recruiting participants.
Verified July 2011 by Shafran Gastroenterology Center
Sponsor:
Collaborator:
UCB, Inc.
Information provided by:
Shafran Gastroenterology Center
ClinicalTrials.gov Identifier:
NCT01053559
First received: January 19, 2010
Last updated: July 19, 2011
Last verified: July 2011

January 19, 2010
July 19, 2011
January 2010
June 2012   (final data collection date for primary outcome measure)
Mucosal Healing [ Time Frame: 180 Days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01053559 on ClinicalTrials.gov Archive Site
CRP Level [ Time Frame: 180 Days ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy
Open Label Investigator Initiated, Single Site Study of Mucosal Healing in Patients With Small Bowel Crohn's Disease Treated With Certolizumab Pegol (Cimzia) Assessed by Wireless Capsule Endoscopy

Wireless Capsule Endoscopy has been the most reliable diagnostic standard for small bowel Crohn's disease. Endoscopic healing is an important endpoint to measure response to treatment.

Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Crohn's Disease
Drug: certolizumab pegol
400mg subcutaneous injections at week 0, week 2, week 4, then every 4 weeks thereafter
Other Name: Cimzia
certolizumab pegol
Subjects will receive FDA approved Cimzia injections as indicated on the product label. Subjects will undergo 3 wireless capsule endoscopies, one at screening,Day 84 and Day 168 as well as monthly bloodwork.
Intervention: Drug: certolizumab pegol
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
5
September 2012
June 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adults aged 18-70 with confirmed Crohn's disease that includes small bowel disease
  • Moderately to severely active disease (CDAI score >220 and < 450
  • Stable doses of steroids, 5 ASA, antibiotics, Immunosuppressants

Exclusion Criteria:

  • Any and all contraindications to the use of certolizumab pegol (including but not limited to hepatitis, infection, abscess, malignancy, CHF, cytopenia)
  • Small bowel obstruction, stricture, or any contraindication for capsule endoscopy
  • Previous treatment with certolizumab pegol
  • Are pregnant or lactating
Both
18 Years to 70 Years
No
Contact: Peggy A Galvis, RN 4076298121 peggaL7@aol.com
Contact: Patricia M. Burgunder, ARNP 4076298121 pburgunder@me.com
United States
 
NCT01053559
Exempt IND
No
Ira Shafran M.D., Shafran Gastroenterology Center
Shafran Gastroenterology Center
UCB, Inc.
Principal Investigator: Ira Shafran, MD Shafran Gastroenterology Center
Shafran Gastroenterology Center
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP